Mizuho Forecasts Strong Price Appreciation for uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QURE) had its target price upped by Mizuho from $7.00 to $20.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a neutral rating on the biotechnology company’s stock.

Other research analysts have also issued research reports about the company. StockNews.com upgraded uniQure to a “sell” rating in a report on Wednesday, December 11th. Leerink Partners raised their price target on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Cantor Fitzgerald upped their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. Stifel Nicolaus raised their target price on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Finally, Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.88.

uniQure Stock Performance

NASDAQ QURE opened at $16.98 on Thursday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $17.71. The business has a fifty day moving average of $8.13 and a 200-day moving average of $6.77. The stock has a market cap of $827.66 million, a price-to-earnings ratio of -3.42 and a beta of 0.89.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, analysts predict that uniQure will post -3.82 earnings per share for the current fiscal year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

Several large investors have recently bought and sold shares of QURE. RTW Investments LP purchased a new position in shares of uniQure in the third quarter valued at $49,000. China Universal Asset Management Co. Ltd. increased its stake in uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares during the period. Atria Investments Inc acquired a new position in uniQure in the 3rd quarter worth $53,000. Quarry LP acquired a new stake in shares of uniQure during the third quarter valued at about $58,000. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.